The platelets’ perspective to pathogen reduction technologies
A wide variety of clinical conditions, associated with low circulating platelet counts, require platelet transfusion in order to normalize hemostatic function. Although single-donor apheresis platelets bear the lowest risk of transfusion-transmitted infections, pathogen reduction technologies (PRT)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-02-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2017.1293806 |
| _version_ | 1827816984325128192 |
|---|---|
| author | Abdimajid Osman Walter E. Hitzler Patrick Provost |
| author_facet | Abdimajid Osman Walter E. Hitzler Patrick Provost |
| author_sort | Abdimajid Osman |
| collection | DOAJ |
| description | A wide variety of clinical conditions, associated with low circulating platelet counts, require platelet transfusion in order to normalize hemostatic function. Although single-donor apheresis platelets bear the lowest risk of transfusion-transmitted infections, pathogen reduction technologies (PRT) are being implemented worldwide to reduce this risk further through inactivation of known, emergent and as yet to be discovered nucleic acid-based pathogens. Human blood platelets are now known to harbor a diverse transcriptome, important to their function and comprised of >5000 protein-coding messenger RNAs and different classes of non-coding RNAs, including microRNAs. Our appreciation of the nucleic acid-dependent functions of platelets is likely to increase. On the other hand, the side effects of PRT on platelet function are underappreciated. Recent evidences suggest that PRT may compromise platelets’ responsiveness to agonists, and induce platelet activation. For instance, platelets have the propensity to release proinflammatory microparticles (MPs) upon activation, and the possibility that PRT may enhance the production of platelet MPs in platelet concentrates (PCs) appears likely. With this in mind, it would be timely and appropriate to investigate other means to inactivate pathogens more specifically, or to modify the currently available PRT so to better preserve the platelet function and improve the safety of PCs; platelets’ perspective to PRT deserves to be considered. |
| first_indexed | 2024-03-12T00:28:03Z |
| format | Article |
| id | doaj.art-4679041cf80e413091e95a970be4aaa7 |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:28:03Z |
| publishDate | 2018-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-4679041cf80e413091e95a970be4aaa72023-09-15T10:31:57ZengTaylor & Francis GroupPlatelets0953-71041369-16352018-02-0129214014710.1080/09537104.2017.12938061293806The platelets’ perspective to pathogen reduction technologiesAbdimajid Osman0Walter E. Hitzler1Patrick Provost2Department of Clinical ChemistryTransfusion Center, University Medical Center of the Johannes Gutenberg University MainzCHUQ Research Center/CHULA wide variety of clinical conditions, associated with low circulating platelet counts, require platelet transfusion in order to normalize hemostatic function. Although single-donor apheresis platelets bear the lowest risk of transfusion-transmitted infections, pathogen reduction technologies (PRT) are being implemented worldwide to reduce this risk further through inactivation of known, emergent and as yet to be discovered nucleic acid-based pathogens. Human blood platelets are now known to harbor a diverse transcriptome, important to their function and comprised of >5000 protein-coding messenger RNAs and different classes of non-coding RNAs, including microRNAs. Our appreciation of the nucleic acid-dependent functions of platelets is likely to increase. On the other hand, the side effects of PRT on platelet function are underappreciated. Recent evidences suggest that PRT may compromise platelets’ responsiveness to agonists, and induce platelet activation. For instance, platelets have the propensity to release proinflammatory microparticles (MPs) upon activation, and the possibility that PRT may enhance the production of platelet MPs in platelet concentrates (PCs) appears likely. With this in mind, it would be timely and appropriate to investigate other means to inactivate pathogens more specifically, or to modify the currently available PRT so to better preserve the platelet function and improve the safety of PCs; platelets’ perspective to PRT deserves to be considered.http://dx.doi.org/10.1080/09537104.2017.1293806nucleic acidspathogen reduction technologiesplatelet activationplatelet concentraterna transcriptome |
| spellingShingle | Abdimajid Osman Walter E. Hitzler Patrick Provost The platelets’ perspective to pathogen reduction technologies Platelets nucleic acids pathogen reduction technologies platelet activation platelet concentrate rna transcriptome |
| title | The platelets’ perspective to pathogen reduction technologies |
| title_full | The platelets’ perspective to pathogen reduction technologies |
| title_fullStr | The platelets’ perspective to pathogen reduction technologies |
| title_full_unstemmed | The platelets’ perspective to pathogen reduction technologies |
| title_short | The platelets’ perspective to pathogen reduction technologies |
| title_sort | platelets perspective to pathogen reduction technologies |
| topic | nucleic acids pathogen reduction technologies platelet activation platelet concentrate rna transcriptome |
| url | http://dx.doi.org/10.1080/09537104.2017.1293806 |
| work_keys_str_mv | AT abdimajidosman theplateletsperspectivetopathogenreductiontechnologies AT walterehitzler theplateletsperspectivetopathogenreductiontechnologies AT patrickprovost theplateletsperspectivetopathogenreductiontechnologies AT abdimajidosman plateletsperspectivetopathogenreductiontechnologies AT walterehitzler plateletsperspectivetopathogenreductiontechnologies AT patrickprovost plateletsperspectivetopathogenreductiontechnologies |